ClinicalTrials.gg
TerminatedNCT03445663Updated Mar 7, 2023

Study Evaluating AMG 424 in Subjects With Multiple Myeloma

A Phase 1 interventional study of AMG 424 in Relapsed/ Refractory Multiple Myeloma, sponsored by Xencor, Inc.. Terminated at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-07.

Sponsored by Xencor, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Previous sponsor business decision not to proceed with the AMG 424 asset.

From the registry’s dates

  • Primary completion was Jun 2020, 6 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,168 studies in Multiple Myeloma with a site in United States — 275 open to participants now, 503 under way, 66 of them phase 3. Multiple Myeloma · United States.

Enrollment
1,176th of 1,901
27 · median 36
Started
2018
with 82 others
Phase 1
559 of 2,168
64 open now
Registered
1,441st of 2,168
by date

Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 1,176th largest by enrollment of the 1,901 interventional ones that give a count, is one of 83 that started in 2018, is one of 559 in phase 1, and was the 1,441st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

275 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

270 more — sign in →

All 275 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,168 studies in Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

A multi-center Phase 1, First-in-Human study conducted in 2 Parts, testing AMG 424 in subjects with relapsed/ refractory multiple myeloma.

Read the detailed description

Part 1 of the study is dose evaluating and aimed at assessing the safety and tolerability of AMG 424 while determining the maximum tolerated dose (MTD) and/or biologically active dose in subjects with relapsed/ refractory multiple myeloma.

Part 2 of the study will further evaluate safety and tolerability of the AMG 424 MTD dose determined in Part 1, in groups of subjects with relapsed/ refractory multiple myeloma that include those with high or low cytogenetic risk.

03

Conditions studied

  • Relapsed/ Refractory Multiple Myeloma

Keywords

  • Relapsed/ Refractory Multiple Myeloma
  • Multiple Myeloma
  • Oncology/Hematology
  • Immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Multiple myeloma meeting the following criteria:
  • -documented diagnosis of multiple myeloma that has after at least two that must include a proteasome inhibitor (PI), immunomodulatory drug (IMiD), and, where approved and available, anti-CD38 therapy in any order OR that is refractory to PI, IMiD, and anti-CD38 therapy.

    ◾Subjects who could not tolerate a PI, IMiDs, or a CD38-directed therapeutic antibody due to unacceptable toxicities are eligible to enroll in the study.

  • as per IMWG response criteria
  • (ECOG) Performance Status of ≤ 2

Exclusion criteria

Exclusion Criteria:

  • Known central nervous system involvement by multiple myeloma
  • Previously received stem cell transplant and one or more of the following:

    • received the transplant \< 6 months prior to study Day 1
    • received therapy \< 3 months prior to study Day 1
    • any active acute (GvHD), grade 2- 4, according to the Glucksberg criteria or active chronic GvHD requiring systemic treatment
    • any systemic therapy against GvHD \< 2 weeks prior to study Day 1
  • Autologous stem cell transplantation less than 90 days prior to study day 1
  • Multiple myeloma with IgM subtype
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  • Evidence of primary or secondary plasma cell leukemia at the time of screening
  • Waldenstrom's macroglobulinemia
  • Amyloidosis
  • Dexamethasone at cumulative doses of greater than 160 mg or equivalent \<3 weeks prior to study Day 1 is not allowed. Use of topical or inhaled is acceptable
  • Anticancer treatment (chemotherapy, IMiD, PI, molecular targeted therapy) \< 2 weeks prior to study Day 1
  • Treatment with a therapeutic antibody targeting CD38 \< 12 weeks prior to study Day 1
  • Systemic radiation therapy or major surgery \< 28 days prior to study Day 1 as well as focal radiotherapy \< 14 days prior to study Day 1.
  • Major surgery within 28 days prior to study Day 1
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    AMG 424

    Comparison of different dosages of AMG 424

    Drug: AMG 424

Interventions

  • DrugAMG 424

    Subjects will receive IV infusions of AMG 424

06

What researchers measure

Primary outcomes

  1. Subject incidence of treatment emergent and treatment related adverse events as assessed by CTCAE version 4.0

    Measure of Safety

    Time frame: 12 Months

  2. Subject incidence of dose limiting toxicities (DLTs)

    Measure of Safety

    Time frame: 28 Days

Secondary outcomes

  1. Anti-tumor activity

    Efficacy parameter measured by IMWG response criteria

    Time frame: 48 Months

  2. Duration of Response

    Measure of Response

    Time frame: 48 Months

  3. Maximum concentration (Cmax) of AMG 424

    Characterize the pharmacokinetic (PK) profile following treatment with AMG 424

    Time frame: 12 Weeks

  4. Minimum concentration (Cmin) of AMG 424

    Characterize the pharmacokinetic (PK) profile following treatment with AMG 424

    Time frame: 12 Weeks

  5. Time of maximum concentration (Tmax) of AMG 424

    Characterize the pharmacokinetic (PK) profile following treatment with AMG 424

    Time frame: 12 Weeks

  6. Area under the concentration-time curve (AUC) of AMG 424

    Characterize the pharmacokinetic (PK) profile following treatment with AMG 424

    Time frame: 12 Weeks

  7. Time to progression

    Measure of Response

    Time frame: 48 Months

  8. Progression-Free Survival

    Measure of Response

    Time frame: 48 Months

  9. Overall Survival

    Measure of Response

    Time frame: 48 Months

07

Study locations

8 sites
  • Research Site
    San Francisco, California 94143, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Winston-Salem, North Carolina 27157, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Seattle, Washington 98104, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    Camperdown, New South Wales 2050, Australia
  • Research Site
    Fitzroy, Victoria 3065, Australia
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Jun 2020, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2018
First posted
Feb 26, 2018
StartActual
Jul 31, 2018
Primary completionActual
Jun 19, 2020
CompletionActual
Jun 19, 2020
Last update
Mar 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03445663
Lead sponsor
Xencor, Inc.
Responsible party
Sponsor
First posted
Feb 26, 2018
Start date
Jul 31, 2018
Primary completion
Jun 19, 2020
Completion
Jun 19, 2020
Last update
Mar 7, 2023

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion